Aster DM Healthcare surges in Q4

Merger momentum builds as profits jump

GSK wins regulatory boost for once-monthly liver drug efimosfermin in MASH push

The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need

Zealand Pharma and Roche charge into Phase 3 with obesity drug bet

The Danish biotech company confirmed the global study will begin in the second half of 2026

AbbVie seeks FDA nod for RINVOQ use in severe alopecia areata

After Phase 3 results show major hair regrowth gains

AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease

The submission is backed by positive results from the Phase 3 AFFIRM study

Cipla wins USFDA nod for first generic of Ventolin HFA strengthening respiratory push

The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA

Evonik bets €80 million on biotech expansion to power next-gen pharma growth

The investment will bring in cutting-edge downstream fermentation technology, strengthening the company’s contract manufacturing capabilities for drug substances

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Astellas & Pfizer win FDA priority review for bladder cancer treatment expansion

A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline

Moderna launches late-stage trial of mRNA bird flu vaccine

The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone